Trial Profile
A case-control, retrospective study to investigate the risk factors for subconjunctival hemorrhage associated with intravitreal injection of Ranibizumab.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 27 Feb 2016
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary)
- Indications Age-related macular degeneration; Choroidal neovascularisation; Degenerative myopia; Diabetic macular oedema; Diabetic retinopathy; Retinal oedema
- Focus Adverse reactions
- 27 Feb 2016 New trial record